Boston Scientific Wraps Up Massive Acquisition of BTG

Boston Scientific announced that it has closed its $4 billion purchase of UK-based BTG, a developer of products used in minimally-invasive cancer and vascular disease procedures.

BTG’s interventional medicine portfolio “reinforces our category leadership strategy and enables us to offer best-in-class technologies, unparalleled clinical evidence and a strengthened commercial infrastructure," said Boston Scientific chairman and CEO Mike Mahoney.

BTG’s interventional medicines portfolio includes products for patients with liver and kidney cancers, while its vascular portfolio offers deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease treatments.